3 research outputs found
Efeitos do treinamento fĂsico sobre a resistĂŞncia mecânica do terço proximal do fĂŞmur de ratos Effects of physical training on the mechanical resistance of rat femur proximal thirds
OBJETIVO: Analisar o comportamento mecânico do terço proximal do fĂŞmur de ratos submetidos ao treinamento aerĂłbio e resistido crĂ´nicos. MÉTODOS: Ratos Wistar machos (80 dias, 300 a 350 g) foram divididos em 3 grupos (n=8 por grupo): Treinamento aerĂłbio/8 semanas (TA), Treinamento resistido/8 semanas (TR) e controle/8 semanas (CO). Ao tĂ©rmino do perĂodo de treinamento os animais foram sacrificados e o fĂŞmur direito coletado. Para análise do comportamento mecânico do fĂŞmur foram realizados ensaios de flexo-compressĂŁo. RESULTADOS: O treinamento resistido ocasionou redução significante da força máxima (Fmáx) do fĂŞmur. Por outro lado, promoveu um aumento (23,7%) relevante, porĂ©m nĂŁo significante, da deformação da força máxima (DFmáx). O treinamento aerĂłbio nĂŁo afetou a Fmáx, porĂ©m promoveu uma redução (26,6%) considerável, tambĂ©m nĂŁo significante, da DFmáx. CONCLUSĂ•ES: Os resultados demonstram que o treinamento resistido e aerĂłbio, promoveram redução da Fmáx e da DFmáx Ăłssea, respectivamente. Os dados evidenciam uma ação diferencial de ambos os modelos de treinamento fĂsico sobre as propriedades mecânicas do fĂŞmur de ratos.<br>OBJECTIVE: To analyze the mechanical behavior of rat femur proximal thirds submitted to chronic aerobic and resistance training. METHODS: Male Wistar rats (80 days of age, weighing 300 to 350 g) were divided into 3 groups (n=8 per group): control (CO), aerobic training (TA) and resistance training (TR). At the end of the training, the animals were euthanized and the right femur was collected. Flexion-compression tests were carried out to analyze the mechanical behavior of the femurs. RESULTS: The resistance training promoted a significant reduction in maximum force (Fmáx) of the femur. However, it also promoted a relevant increase (23.7%), though without statistical significance, in maximum force deformation (DFmáx). The aerobic training did not affect maximum force, however, it caused a considerable reduction in DFmáx (26.6%), though this was also not statistically significant. CONCLUSIONS: The results show that resistance and aerobic training promoted a reduction in the Fmáx and DFmáx, respectively. The data showed a different response of both physical training models on the mechanical properties of the rat femurs
Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)
ABSTRACT Background: Cases of coronavirus disease 2019 (COVID-19) requiring hospitalization continue to appear in vulnerable populations, highlighting the importance of novel treatments. The hyperinflammatory response underlies the severity of the disease, and targeting this pathway may be useful. Herein, we tested whether immunomodulation focusing on interleukin (IL)-6, IL-17, and IL-2, could improve the clinical outcomes of patients admitted with COVID-19. Methods: This multicenter, open-label, prospective, randomized controlled trial was conducted in Brazil. Sixty hospitalized patients with moderate-to-critical COVID-19 received in addition to standard of care (SOC): IL-17 inhibitor (ixekizumab 80 mg SC/week) 1 dose every 4 weeks; low-dose IL-2 (1.5 million IU per day) for 7 days or until discharge; or indirect IL-6 inhibitor (colchicine) orally (0.5 mg) every 8 hours for 3 days, followed by 4 weeks at 0.5 mg 2x/day; or SOC alone. The primary outcome was accessed in the “per protocol” population as the proportion of patients with clinical improvement, defined as a decrease greater or equal to two points on the World Health Organization’s (WHO) seven-category ordinal scale by day 28. Results: All treatments were safe, and the efficacy outcomes did not differ significantly from those of SOC. Interestingly, in the colchicine group, all participants had an improvement of greater or equal to two points on the WHO seven-category ordinal scale and no deaths or patient deterioration were observed. Conclusions: Ixekizumab, colchicine, and IL-2 were demonstrated to be safe but ineffective for COVID-19 treatment. These results must be interpreted cautiously because of the limited sample size